Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chinese PLA Generation Hospital
Brief Summary: Background: Malignant peritoneal adhesion is a common complication and prognostic factor of ovarian cancer and other primary abdominal tumors. The incidence of peritoneal adhesion in advanced primary peritoneal tumor is 32-56%, which has increased by more than 10 times in the recent decade. Malignant peritoneal adhesion is closely associated with the morbidity and mortality of malignant intestinal obstruction. The peritoneal adhesion may aggravates the abdominal symptoms and reduce quality of life. Further, the peritoneal adhesion may impede treatment of primary tumor, such as operation or chemotherapy, lead to a poor prognosis.

Objective: This study aims to treat malignant peritoneal adhesion with the combination of antiangiogenic agent and chemotherapy, evaluate the efficacy and safety of intraperitoneal antiangiogenic agent plus chemotherapy. As explosive endpoints, we will examination the expression of VEGF-A in peritoneal cavity during the treatment.


Options:
A: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets
B: Arm Label: olaparib + cediranib; Type: EXPERIMENTAL; Interventions: Drug: olaparib+cediranib combination therapy | Arm Label: durvalumab + olaparib; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + olaparib combination therapy | Arm Label: durvalumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + paclitaxel treatment | Arm Label: durvalumab +chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab +chemotherapy treatment | Intervention Type: DRUG; Name: olaparib+cediranib combination therapy; Assigned to Arm(s): olaparib + cediranib | Intervention Type: DRUG; Name: durvalumab + olaparib combination therapy; Assigned to Arm(s): durvalumab + olaparib | Intervention Type: DRUG; Name: durvalumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + tremelimumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + paclitaxel treatment; Assigned to Arm(s): durvalumab + tremelimumab + paclitaxel | Intervention Type: DRUG; Name: durvalumab +chemotherapy treatment; Assigned to Arm(s): durvalumab +chemotherapy
C: Arm Label: Intraperitoneal bevacizumab+ carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Carboplatin, Drug: paclitaxel | Arm Label: Intraperitoneal carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin
D: Arm Label: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active comparator: Niraparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Active comparator: Niraparib; Assigned to Arm(s): Niraparib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C